IDEAYA Biosciences Stock

IDEAYA Biosciences Market capitalization 2024

IDEAYA Biosciences Market capitalization

2.44 B USD

Ticker

IDYA

ISIN

US45166A1025

WKN

A2PJPB

In 2024, IDEAYA Biosciences's market cap stood at 2.44 B USD, a 67.4% increase from the 1.46 B USD market cap in the previous year.

The IDEAYA Biosciences Market capitalization history

YEARMarket Capitalization (undefined USD)
20231.33
20220.58
20210.75
20200.25
20190.1
2018-
2017-

IDEAYA Biosciences Aktienanalyse

What does IDEAYA Biosciences do?

IDEAYA Biosciences Inc is a biotechnology company focused on the development of cancer therapies. The company was founded in 2015 by Yujiro S. Hata and is headquartered in South San Francisco, California. IDEAYA's business model consists of the discovery and development of precision medicine products based on targeted therapies. Targeted therapies are cancer treatments that aim at the specific characteristics of the tumor and have less harmful effects on normal tissue than traditional chemotherapeutics. IDEAYA specializes in the research and development of cancer drugs in three different areas: precision medicine, synthetic lethality, and resistance mechanisms. The company collaborates closely with leading experts in cancer research to develop innovative therapies. In the field of precision medicine, IDEAYA focuses on the development of products based on genetic alterations that cause specific tumors. These genetic alterations are unique to each type of cancer and each individual, meaning that precision medicine products must be individually tailored to each type of cancer. In the area of synthetic lethality, IDEAYA examines the interactions between cancer cells and their environment. These interactions can involve genetic or proteomic changes that make cancer cells dependent on certain signaling pathways and metabolic processes. IDEAYA develops drugs that exploit these dependencies to block the growth of cancer cells. In the area of resistance mechanisms, IDEAYA investigates the mechanisms that cancer cells develop to become resistant to cancer drugs. This involves the discovery of compounds that can bypass these mechanisms and make the cancer cells sensitive to treatments again. IDEAYA has several products in the pipeline, including Inhibat (IDE196) and polyclonal antibodies. Inhibat (IDE196) is a potent and highly selective BRAF inhibitor used in clinical trials for cancer. Polyclonal antibodies are monoclonal antibodies used in cancer immunotherapy. IDEAYA is a company focused on the development of innovative cancer drugs. The company has a solid foundation in cancer research and works closely with leading experts to develop innovative therapies. The company has several products in the pipeline and is working hard to make a significant contribution in cancer research. IDEAYA Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring IDEAYA Biosciences's Market Capitalization

IDEAYA Biosciences's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of IDEAYA Biosciences's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

IDEAYA Biosciences's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in IDEAYA Biosciences’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about IDEAYA Biosciences stock

What is the current IDEAYA Biosciences market capitalization?

The current market capitalization of IDEAYA Biosciences is 2.44 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like IDEAYA Biosciences.

How has the market capitalization of IDEAYA Biosciences developed in recent years?

The market capitalization of IDEAYA Biosciences has increased/decreased by 67.4% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of IDEAYA Biosciences?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of IDEAYA Biosciences?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of IDEAYA Biosciences have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does IDEAYA Biosciences pay?

Over the past 12 months, IDEAYA Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IDEAYA Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IDEAYA Biosciences?

The current dividend yield of IDEAYA Biosciences is .

When does IDEAYA Biosciences pay dividends?

IDEAYA Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IDEAYA Biosciences?

IDEAYA Biosciences paid dividends every year for the past 0 years.

What is the dividend of IDEAYA Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IDEAYA Biosciences located?

IDEAYA Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IDEAYA Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IDEAYA Biosciences from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.

When did IDEAYA Biosciences pay the last dividend?

The last dividend was paid out on 8/2/2024.

What was the dividend of IDEAYA Biosciences in the year 2023?

In the year 2023, IDEAYA Biosciences distributed 0 USD as dividends.

In which currency does IDEAYA Biosciences pay out the dividend?

The dividends of IDEAYA Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IDEAYA Biosciences

Our stock analysis for IDEAYA Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDEAYA Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.